Sixiang Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sixiang Shi has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Weibo Cai
University of Wisconsin−Madison
31 shared publications Hao Hong
The Departments of Radiology and Medical Physics, University of Wisconsin, Madison, Wisconsin 53706, and
18 shared publications- Shreya Goel
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA
17 shared publications Feng Chen
Department of Radiology, University of Wisconsin-Madison, Madison, USA
15 shared publications- Stephen A. Graves
Department of Radiology, The University of Iowa, Iowa City, IA 52242, USA
13 shared publications - Todd E. Barnhart
Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, USA
12 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaef0121
FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 ( 225 Ac), for treating refractory cancers have opened avenues for improved therapeutic options. Here, we describe a successful example of folate receptor 1 (FOLR1)–targeted 225 Ac alpha-particle therapy for treatment of ovarian cancer. Longitudinal positron emission tomography imaging demonstrated high tumor-specific uptake of αFOLR1 (anti-FOLR1 antibody) in SKOV3 xenografts. FOLR1-targeted 225 Ac demonstrated high therapeutic efficacy, achieving marked tumor regression, 80% survival, and 40% complete tumor elimination. The therapy resulted in tumor-specific double-stranded DNA damage, and no obvious toxicity was observed in normal tissues. Estimated human dosimetry showed high absorbed dose for tumor and minimal absorbed dose for healthy tissues, establishing its safety. In totality, FOLR1-targeted 225 Ac alpha-particle therapy is an efficacious and safe treatment with high feasibility for clinical translation to fight against ovarian cancer.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaef0121
Open AccessFOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 ( 225 Ac), for treating refractory cancers have opened avenues for improved therapeutic options. Here, we describe a successful example of folate receptor 1 (FOLR1)–targeted 225 Ac alpha-particle therapy for treatment of ovarian cancer. Longitudinal positron emission tomography imaging demonstrated high tumor-specific uptake of αFOLR1 (anti-FOLR1 antibody) in SKOV3 xenografts. FOLR1-targeted 225 Ac demonstrated high therapeutic efficacy, achieving marked tumor regression, 80% survival, and 40% complete tumor elimination. The therapy resulted in tumor-specific double-stranded DNA damage, and no obvious toxicity was observed in normal tissues. Estimated human dosimetry showed high absorbed dose for tumor and minimal absorbed dose for healthy tissues, establishing its safety. In totality, FOLR1-targeted 225 Ac alpha-particle therapy is an efficacious and safe treatment with high feasibility for clinical translation to fight against ovarian cancer.
- Open Access
- 6 June 2026
- Published by Elsevier in SSRN Electronic Journal
Cardiomyocytes Drive [18F]-FDG Uptake in Arrhythmogenic Cardiomyopathy
Background: Arrhythmogenic cardiomyopathy (ACM) is a heritable cardiac disease characterized by arrhythmias, progressive myocardial injury, and sudden death. Inflammation is central to disease progression. 2-deoxy-2-[18F]-Fluoroglucose positron emission tomography ([18F]FDG PET) is increasingly used to identify glycolytically active immune cells in inflammatory cardiomyopathies. However, whether [18F]FDG uptake in ACM reflects myocardial immune cell recruitment remains unclear. Methods and Results: We performed cardiac [18F]FDG PET imaging in wild-type and desmoglein-2 (DSG2) mutant mice, a well established model of ACM, followed by immune cell profiling using flow cytometry. DSG2 mutant mice exhibited significantly increased cardiac [18F]FDG uptake compared with wild type controls. Although both CCR2+ and CCR2- macrophage populations correlated with the [18F]FDG uptake, pharmacologic depletion of macrophages with liposomal clodronate did not reduce [18F]FDG uptake. High resolution confocal microscopy using the fluorescent glucose analog 2-NBDG demonstrated increased uptake localized predominantly to cardiomyocytes in DSG2 mutant hearts.Conclusions: Myocardial [18F]FDG uptake is not dependent on macrophage abundance and is predominantly localized to cardiomyocytes. These findings suggest that [18F]FDG uptake reflects cardiomyocyte metabolic remodeling driven by cell-intrinsic inflammatory signaling pathways, rather than serving as a direct marker of immune cell infiltration.
- 6 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCardiomyocytes Drive [18F]-FDG Uptake in Arrhythmogenic Cardiomyopathy
Background: Arrhythmogenic cardiomyopathy (ACM) is a heritable cardiac disease characterized by arrhythmias, progressive myocardial injury, and sudden death. Inflammation is central to disease progression. 2-deoxy-2-[18F]-Fluoroglucose positron emission tomography ([18F]FDG PET) is increasingly used to identify glycolytically active immune cells in inflammatory cardiomyopathies. However, whether [18F]FDG uptake in ACM reflects myocardial immune cell recruitment remains unclear. Methods and Results: We performed cardiac [18F]FDG PET imaging in wild-type and desmoglein-2 (DSG2) mutant mice, a well established model of ACM, followed by immune cell profiling using flow cytometry. DSG2 mutant mice exhibited significantly increased cardiac [18F]FDG uptake compared with wild type controls. Although both CCR2+ and CCR2- macrophage populations correlated with the [18F]FDG uptake, pharmacologic depletion of macrophages with liposomal clodronate did not reduce [18F]FDG uptake. High resolution confocal microscopy using the fluorescent glucose analog 2-NBDG demonstrated increased uptake localized predominantly to cardiomyocytes in DSG2 mutant hearts.Conclusions: Myocardial [18F]FDG uptake is not dependent on macrophage abundance and is predominantly localized to cardiomyocytes. These findings suggest that [18F]FDG uptake reflects cardiomyocyte metabolic remodeling driven by cell-intrinsic inflammatory signaling pathways, rather than serving as a direct marker of immune cell infiltration.
- Open Access
Copper Sulfide Nanoparticle–Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells
Immunotherapy has only limited efficacy against ovarian cancer because of dysfunctional T cells in an immunosuppressive tumor microenvironment. Selective photothermolysis is a technique in which short pulsed laser is used to ablate tissue in targeted regions in a precise spatiotemporally controlled manner. This technique allows targeted tissue ablation without damage to surrounding tissue. In the current study, we demonstrated that ovarian cancer cells treated with photothermolysis mediated by near-infrared-absorbing CuS nanoparticles and 15-ns laser pulses were ingested by human monocyte-derived dendritic cells (MoDCs) more efficiently than were ovarian cancer cells treated with ionizing radiation. Moreover, ingestion of ovarian cancer cells treated with CuS NP-mediated photothermolysis promoted MoDC activation. Immature MoDCs that had been exposed to photothermolysis-treated cancer cells caused greater clonal expansion of co-cultured human CD4 + and CD8 + T cells than did immature MoDCs that had been exposed to ionizing radiation–treated tumor cells. These data indicate that photothermolysis may be used to selectively target and destroy tumor cells and cause them to release antigens and danger signals, which can be recognized by DCs to activate T cells.
Open AccessCopper Sulfide Nanoparticle–Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells
Immunotherapy has only limited efficacy against ovarian cancer because of dysfunctional T cells in an immunosuppressive tumor microenvironment. Selective photothermolysis is a technique in which short pulsed laser is used to ablate tissue in targeted regions in a precise spatiotemporally controlled manner. This technique allows targeted tissue ablation without damage to surrounding tissue. In the current study, we demonstrated that ovarian cancer cells treated with photothermolysis mediated by near-infrared-absorbing CuS nanoparticles and 15-ns laser pulses were ingested by human monocyte-derived dendritic cells (MoDCs) more efficiently than were ovarian cancer cells treated with ionizing radiation. Moreover, ingestion of ovarian cancer cells treated with CuS NP-mediated photothermolysis promoted MoDC activation. Immature MoDCs that had been exposed to photothermolysis-treated cancer cells caused greater clonal expansion of co-cultured human CD4 + and CD8 + T cells than did immature MoDCs that had been exposed to ionizing radiation–treated tumor cells. These data indicate that photothermolysis may be used to selectively target and destroy tumor cells and cause them to release antigens and danger signals, which can be recognized by DCs to activate T cells.
- Open Access
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadv2930
Image-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy
Tumor hypoxia leads to radioresistance and markedly worse clinical outcomes for pediatric malignant rhabdoid tumors (MRTs). Our transcriptomics and bioenergetic profiling data reveal that mitochondrial oxidative phosphorylation is a metabolic vulnerability of MRT and can be exploited to overcome consumptive hypoxia by repurposing an FDA-approved antimalarial drug, atovaquone (AVO). We then establish the utility of oxygen-enhanced-multispectral optoacoustic tomography, a label-free, ionizing radiation-free imaging modality, to visualize and quantify spatiotemporal changes in tumor hypoxia in response to AVO. We show a potent but transient increase in tumor oxygenation upon AVO treatment that results in complete elimination of tumors in all tested mice when combined with 10-gray radiotherapy, a dose several times lower than the current clinic standard. Last, we use translational mathematical modeling for systematic evaluation of dosing regimens, administration timing, and therapeutic synergy in a virtual patient cohort. Together, our work establishes a framework for safe and pediatric patient-friendly image-guided metabolic radiosensitization of rhabdoid tumors.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadv2930
Open AccessImage-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy
Tumor hypoxia leads to radioresistance and markedly worse clinical outcomes for pediatric malignant rhabdoid tumors (MRTs). Our transcriptomics and bioenergetic profiling data reveal that mitochondrial oxidative phosphorylation is a metabolic vulnerability of MRT and can be exploited to overcome consumptive hypoxia by repurposing an FDA-approved antimalarial drug, atovaquone (AVO). We then establish the utility of oxygen-enhanced-multispectral optoacoustic tomography, a label-free, ionizing radiation-free imaging modality, to visualize and quantify spatiotemporal changes in tumor hypoxia in response to AVO. We show a potent but transient increase in tumor oxygenation upon AVO treatment that results in complete elimination of tumors in all tested mice when combined with 10-gray radiotherapy, a dose several times lower than the current clinic standard. Last, we use translational mathematical modeling for systematic evaluation of dosing regimens, administration timing, and therapeutic synergy in a virtual patient cohort. Together, our work establishes a framework for safe and pediatric patient-friendly image-guided metabolic radiosensitization of rhabdoid tumors.
- Open Access
- 8 April 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (15) , 8474-8482
Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model
Purpose: Among the treatment options for pancreatic ductal adenocarcinoma (PDAC) are antibodies against the programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway. Positron emission tomography (PET) has been successfully used to assess PD-1/PD-L1 signaling in subcutaneous tumor models, but orthotopic tumor models are increasingly being recognized as a better option to accurately recapitulate human disease. However, when PET radiotracers have high uptake in the liver and spleen, it can obscure signals from the adjacent pancreas, making visualization of the response in orthotopic pancreatic tumors technically challenging. In this study, we first investigated the impact of radioisotope chelators on the biodistribution of 64Cu-labeled anti-PD-1 and anti-PD-L1 antibodies and compared the distribution profiles of anti-PD-1 and anti-PD-L1 antibodies. We then tested the hypothesis that co-injection of unlabeled antibodies reduces uptake of 64Cu-labeled anti-PD-L1 antibodies in the spleen and thereby permits accurate delineation of orthotopic pancreatic tumors in mice. Procedures: We established subcutaneous and orthotopic mouse models of PDAC using KRAS* murine pancreatic cancer cells with a doxycycline-inducible mutation of KRASG12D. We then (1) compared the biodistribution of 64Cu-labeled anti-PD-1 with 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA) and 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) used as the chelators in the orthotopic model; (2) compared the biodistribution of [64Cu]Cu-NOTA-anti-PD-1 and [64Cu]Cu-NOTA-anti-PD-L1 in the orthotopic model; and (3) imaged subcutaneous and orthotopic KRAS* tumors with [64Cu]Cu-NOTA-anti-PD-L1 with and without co-injection of unlabeled anti-PD-L1 as the blocking agent. Results: [64Cu]Cu-NOTA-anti-PD-L1 was a promising imaging probe. By co-injection of an excess of unlabeled anti-PD-L1, background signals of [64Cu]Cu-NOTA-anti-PD-L1 from the spleen were significantly reduced, leading to a clear delineation of orthotopic pancreatic tumors. Conclusions: Co-injection with unlabeled anti-PD-L1 is a useful method for PET imaging of PD-L1 expression in orthotopic pancreatic cancer models.
- 8 April 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (15) , 8474-8482
Open AccessConcurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model
Purpose: Among the treatment options for pancreatic ductal adenocarcinoma (PDAC) are antibodies against the programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway. Positron emission tomography (PET) has been successfully used to assess PD-1/PD-L1 signaling in subcutaneous tumor models, but orthotopic tumor models are increasingly being recognized as a better option to accurately recapitulate human disease. However, when PET radiotracers have high uptake in the liver and spleen, it can obscure signals from the adjacent pancreas, making visualization of the response in orthotopic pancreatic tumors technically challenging. In this study, we first investigated the impact of radioisotope chelators on the biodistribution of 64Cu-labeled anti-PD-1 and anti-PD-L1 antibodies and compared the distribution profiles of anti-PD-1 and anti-PD-L1 antibodies. We then tested the hypothesis that co-injection of unlabeled antibodies reduces uptake of 64Cu-labeled anti-PD-L1 antibodies in the spleen and thereby permits accurate delineation of orthotopic pancreatic tumors in mice. Procedures: We established subcutaneous and orthotopic mouse models of PDAC using KRAS* murine pancreatic cancer cells with a doxycycline-inducible mutation of KRASG12D. We then (1) compared the biodistribution of 64Cu-labeled anti-PD-1 with 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA) and 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) used as the chelators in the orthotopic model; (2) compared the biodistribution of [64Cu]Cu-NOTA-anti-PD-1 and [64Cu]Cu-NOTA-anti-PD-L1 in the orthotopic model; and (3) imaged subcutaneous and orthotopic KRAS* tumors with [64Cu]Cu-NOTA-anti-PD-L1 with and without co-injection of unlabeled anti-PD-L1 as the blocking agent. Results: [64Cu]Cu-NOTA-anti-PD-L1 was a promising imaging probe. By co-injection of an excess of unlabeled anti-PD-L1, background signals of [64Cu]Cu-NOTA-anti-PD-L1 from the spleen were significantly reduced, leading to a clear delineation of orthotopic pancreatic tumors. Conclusions: Co-injection with unlabeled anti-PD-L1 is a useful method for PET imaging of PD-L1 expression in orthotopic pancreatic cancer models.
- 27 September 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (10) , 2675-2683
Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention
Exosomes have attracted tremendous attention due to their important role in physiology, pathology, and oncology, as well as promising potential in biomedical applications. Although great efforts have been dedicated to investigating their biological properties and applications as natural cancer drug-delivery systems, the systemic biodistribution of exosomes remains underexplored. In addition, exosome-based drug delivery is inevitably hindered by the robust liver clearance, leading to suboptimal tumor retention and therapeutic efficiency. In this study, we report one of the first examples using in vivo positron emission tomography (PET) for noninvasive monitoring of copper-64 (64Cu)-radiolabeled polyethylene glycol (PEG)-modified exosomes, achieving excellent imaging quality and quantitative measurement of blood residence and tumor retention. PEGylation not only endowed exosomes with a superior pharmacokinetic profile and great accumulation in the tumor versus traditionally reported native exosomes but also reduced premature hepatic sequestration and clearance of exosomes, findings that promise enhanced therapeutic delivery efficacy and safety in future studies. More importantly, this study provides important guidelines about surface engineering, radiochemistry, and molecular imaging in obtaining accurate and quantitative biodistribution information on exosomes, which may benefit future exploration in the realm of exosomes.
- 27 September 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (10) , 2675-2683
Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention
Exosomes have attracted tremendous attention due to their important role in physiology, pathology, and oncology, as well as promising potential in biomedical applications. Although great efforts have been dedicated to investigating their biological properties and applications as natural cancer drug-delivery systems, the systemic biodistribution of exosomes remains underexplored. In addition, exosome-based drug delivery is inevitably hindered by the robust liver clearance, leading to suboptimal tumor retention and therapeutic efficiency. In this study, we report one of the first examples using in vivo positron emission tomography (PET) for noninvasive monitoring of copper-64 (64Cu)-radiolabeled polyethylene glycol (PEG)-modified exosomes, achieving excellent imaging quality and quantitative measurement of blood residence and tumor retention. PEGylation not only endowed exosomes with a superior pharmacokinetic profile and great accumulation in the tumor versus traditionally reported native exosomes but also reduced premature hepatic sequestration and clearance of exosomes, findings that promise enhanced therapeutic delivery efficacy and safety in future studies. More importantly, this study provides important guidelines about surface engineering, radiochemistry, and molecular imaging in obtaining accurate and quantitative biodistribution information on exosomes, which may benefit future exploration in the realm of exosomes.
- 4 July 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (8) , 3203-3211
Thermosensitive Biodegradable Copper Sulfide Nanoparticles for Real-Time Multispectral Optoacoustic Tomography
Although multifunctional inorganic nanoparticles have been extensively explored for effective cancer diagnosis and therapy, their clinical translation has been greatly impeded because of significant uptake in the reticuloendothelial system and concerns about potential toxicity. In this study, we uncovered the thermosensitive biodegradability of CuS nanoparticles, which have classically been considered as stable in a bulk state. Polyethylene glycol (PEG)-coated CuS nanoparticles (CuS-PEG) were well-preserved at 4 °C but were rapidly degraded at 37 °C within 1 week in both in vitro and in vivo tests. Furthermore, real-time multispectral optoacoustic tomography, which is more convenient and accurate than traditional ex vivo analysis, was successfully employed to noninvasively demonstrate the biodegradability of CuS-PEG nanoparticles and dynamically monitor their tumor imaging capacity. The temperature-dependent controllable degradation profile and excellent tumor retention of CuS-PEG nanoparticles endow them with great potential for clinical applications since it ensures that the nanoparticles remain intact during production, transportation, and storage but degrade and clear from the body at a physiological temperature after accomplishing sufficient diagnosis and therapeutic operations.
- 4 July 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (8) , 3203-3211
Thermosensitive Biodegradable Copper Sulfide Nanoparticles for Real-Time Multispectral Optoacoustic Tomography
Although multifunctional inorganic nanoparticles have been extensively explored for effective cancer diagnosis and therapy, their clinical translation has been greatly impeded because of significant uptake in the reticuloendothelial system and concerns about potential toxicity. In this study, we uncovered the thermosensitive biodegradability of CuS nanoparticles, which have classically been considered as stable in a bulk state. Polyethylene glycol (PEG)-coated CuS nanoparticles (CuS-PEG) were well-preserved at 4 °C but were rapidly degraded at 37 °C within 1 week in both in vitro and in vivo tests. Furthermore, real-time multispectral optoacoustic tomography, which is more convenient and accurate than traditional ex vivo analysis, was successfully employed to noninvasively demonstrate the biodegradability of CuS-PEG nanoparticles and dynamically monitor their tumor imaging capacity. The temperature-dependent controllable degradation profile and excellent tumor retention of CuS-PEG nanoparticles endow them with great potential for clinical applications since it ensures that the nanoparticles remain intact during production, transportation, and storage but degrade and clear from the body at a physiological temperature after accomplishing sufficient diagnosis and therapeutic operations.
- 1 April 2019
- Published by Elsevier in Acta Biomaterialia
- Vol. 89, 1-13
Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer
- 1 April 2019
- Published by Elsevier in Acta Biomaterialia
- Vol. 89, 1-13
Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (3) , 853-867
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth
Rationale: The expression of the chemokine (C-X-C motif) ligand 1 (CXCL1), an inflammatory protein, has been reported to be up-regulated in many human cancers. The mechanisms through which aberrant cellular CXCL1 levels promote specific steps in tumor growth and progression are unknown.
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (3) , 853-867
Open AccessMonoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth
Rationale: The expression of the chemokine (C-X-C motif) ligand 1 (CXCL1), an inflammatory protein, has been reported to be up-regulated in many human cancers. The mechanisms through which aberrant cellular CXCL1 levels promote specific steps in tumor growth and progression are unknown.
- 8 November 2018
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (12) , 4062-4071
Integrin αvβ3-Targeted [64Cu]CuS Nanoparticles for PET/CT Imaging and Photothermal Ablation Therapy
Copper sulfide (CuS) nanoparticles have been considered one of the most clinical relevant nanosystems because of their straightforward chemistry, small particle size, low toxicity, and intrinsic theranostic characteristics. In our previous studies, radioactive [64Cu]CuS nanoparticles were successfully developed to be used as efficient radiotracers for positron emission tomography and for photothermal ablation therapy of cancer cells using near-infrared laser irradiation. However, the major challenge of CuS nanoparticles as a theranostic platform is the lack of a means for effective targeted delivery to the tumor site. To overcome this challenge, we designed and synthesized angiogenesis-targeting [64Cu]CuS nanoparticles, which are coupled with cyclic RGDfK peptide [c(RGDfK)] through polyethylene glycol (PEG) linkers using click chemistry. In assessing their tumor-targeting efficacy, we found that the tumor uptakes of [64Cu]CuS-PEG-c(RGDfK) nanoparticles at 24 h after intravenous injection were significantly greater (8.6%±1.4% injected dose/gram of tissue) than those of nontargeted [64Cu]CuS-PEG nanoparticles (4.3%±1.2% injected dose/gram of tissue, p < 0.05). Irradiation of tumors in mice administered [64Cu]CuS-PEG-c(RGDfK) nanoparticles induced 98.7% necrotic areas. In contrast, irradiation of tumors in mice administered non-targeted CuS-PEG nanoparticles induced 59% necrotic areas (p < 0.05). The angiogenesis-targeting [64Cu]CuS nanoparticles may serve as a promising platform for image-guided ablation therapy with high efficacy and minimal side effects in future clinical translation of this novel class of multifunctional nanomaterials.
- 8 November 2018
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (12) , 4062-4071
Integrin αvβ3-Targeted [64Cu]CuS Nanoparticles for PET/CT Imaging and Photothermal Ablation Therapy
Copper sulfide (CuS) nanoparticles have been considered one of the most clinical relevant nanosystems because of their straightforward chemistry, small particle size, low toxicity, and intrinsic theranostic characteristics. In our previous studies, radioactive [64Cu]CuS nanoparticles were successfully developed to be used as efficient radiotracers for positron emission tomography and for photothermal ablation therapy of cancer cells using near-infrared laser irradiation. However, the major challenge of CuS nanoparticles as a theranostic platform is the lack of a means for effective targeted delivery to the tumor site. To overcome this challenge, we designed and synthesized angiogenesis-targeting [64Cu]CuS nanoparticles, which are coupled with cyclic RGDfK peptide [c(RGDfK)] through polyethylene glycol (PEG) linkers using click chemistry. In assessing their tumor-targeting efficacy, we found that the tumor uptakes of [64Cu]CuS-PEG-c(RGDfK) nanoparticles at 24 h after intravenous injection were significantly greater (8.6%±1.4% injected dose/gram of tissue) than those of nontargeted [64Cu]CuS-PEG nanoparticles (4.3%±1.2% injected dose/gram of tissue, p < 0.05). Irradiation of tumors in mice administered [64Cu]CuS-PEG-c(RGDfK) nanoparticles induced 98.7% necrotic areas. In contrast, irradiation of tumors in mice administered non-targeted CuS-PEG nanoparticles induced 59% necrotic areas (p < 0.05). The angiogenesis-targeting [64Cu]CuS nanoparticles may serve as a promising platform for image-guided ablation therapy with high efficacy and minimal side effects in future clinical translation of this novel class of multifunctional nanomaterials.